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Muscular dystrophy (MD) is one of the most frequently inherited diseases, yet 
few science, technology, and society (STS) scholars have attempted to study it. In 
particular, there is a significant gap in the literature regarding how sociocultural 
contexts have shaped biomedical perspectives on the disease. Therefore, this thesis 
adopts Paul Rabinow’s notion of biosociality and traces the history of muscular 
dystrophy to draw conclusions about how and what kinds of knowledge about MD are 
produced as biological fact. The first chapter, which analyzes early descriptions of 
muscular dystrophy, demonstrates that modern perspectives on correct ways of knowing 
in turn influence who scientists credit with “discovering” MD. Similarly, the second 
chapter reveals how diagnostic technologies help define the boundaries of disease. 
Ultimately, this thesis serves as a case study to prove that science does not stand apart 
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When Conner Curran was four years old, a doctor told his parents, “Take your 
son home, love him, take him on trips while he’s walking, give him a good life and 
enjoy him…”1 The implicit message was clear: Conner’s days were numbered. He had 
just been diagnosed with Duchenne muscular dystrophy, a debilitating disease that 
meant he would be fortunate to survive to early adulthood.2 
Today, scientists and medical professionals use “muscular dystrophy” as a 
blanket term to cover a large group of diseases characterized by progressive muscle 
weakness. In everyday language, however, muscular dystrophy (MD) more commonly 
refers to the dystrophinopathies, a subcategory of MD that includes Duchenne muscular 
dystrophy (DMD) and Becker muscular dystrophy (BMD), which are both 
characterized by weakness in the limbs, enlarged calves, and eventual heart failure.3 
The group of myopathies included under the umbrella of muscular dystrophy is ever-
evolving, largely because MD, like many diseases, is now being analyzed at the genetic 
level; as of late 2019, scientists believed muscular dystrophy could be connected to the 
disfunction of more than forty genes, and thus more than forty diseases.4 As the 
scientific understanding of MD continues to evolve, so, too, do ideas about its 
                                                        
1 Jon Hamilton, “A Boy with Muscular Dystrophy was Headed for a Wheelchair. Then Gene Therapy 
Arrived,” Shots: Health News from NPR, NPR, July 27, 2020, https://www.npr.org/sections/health-
shots/2020/07/27/893289171/a-boy-with-muscular-dystrophy-was-headed-for-a-wheelchair-then-gene-
therapy-arri. 
2 Basil T. Darras, David K. Urion, and Partha S. Ghosh, “Dystrophinopathies,” in GeneReviews, ed. 
Margaret P. Adam, Holly, H. Ardinger, Roberta A. Pagon, Stephanie E. Wallace, Lora J. H. Bean, 
Ghayda Mirzaa, and Anna Amemiya (Seattle: University of Washington, Seattle, 2000), 
https://www.ncbi.nlm.nih.gov/books/NBK1116/. 
3 Darras, Urion, and Ghosh, “Dystrophinopathies.”    
4 Eugenio Mercuri, Carsten G. Bönnemann, and Francesco Muntoni, “Muscular Dystrophies,” Lancet 





classification and diagnosis. Accordingly, this thesis aims to study the changing 
narrative of “disease” in the Western history of muscular dystrophy. What did it mean 
to have muscular dystrophy before scientists began to fully characterize its genetic 
bases, and how do these answers differ in the postgenomic age of the 21st century? 
Addressing these and related questions will demonstrate that muscular dystrophy does 
not exist in a purely “scientific” vacuum, as science itself is inevitably molded by 
society. Furthermore, some of the conclusions drawn from this research will be able 
extend to other genetic diseases and disorders, as the technologies and societal changes 
that have helped shape how biomedical professionals view muscular dystrophy have 
undoubtedly influenced perceptions of other diseases with genetic components. 
Literature Review 
Although muscular dystrophy is a thriving area of research for scientists, little 
work has been done to move studies of MD beyond the biomedical into a cultural 
context. This is surprising considering the incidence of the Duchenne type alone is 
between 1 in 3,500 and 1 in 5,000, making it one of the most common heritable diseases 
in the world.5 The limited research on MD outside of a scientific realm has bifurcated 
into two main foci: studies of MD organizations and ethnographies of patients’ 
experience, particularly within “the clinic,” as popularized by Michel Foucault.6 In the 
first category, French sociologists and frequent collaborators Vololona Rabeharisoa and 
                                                        
5 Alan E. H. Emery, “Population Frequencies of Inherited Neuromuscular Diseases – A World Survey,” 
Neuromuscular Disorders 1, no. 1 (1991): 21, doi: 10.1016/0960-8966(91)90039-U; Simon Guiraud et 
al., “The Pathogenesis and Therapy of Muscular Dystrophies,” Annual Review of Genomics and Human 
Genetics 16 (2015): 281-308, doi: 10.1146/annurev-genom-090314-025003. 
6 Michel Foucault, The Birth of the Clinic: An Archaeology of Medical Perception, trans. A. M. Sheridan 





Michel Callon have been particularly influential. Their first book, Le Pouvoir des 
Malades: l’Association Française Contre les Myopathies & la Recherche traces the 
history of the French Muscular Dystrophy Association (AFM) and examines the ways 
in which laypeople and specialists interact with each other.7 Their subsequent English-
language publications have continued to research the influence of the AFM in 
producing biomedical knowledge.8 In comparison, other scholars have moved away 
from studying organizations to studying patient identity. Two Canadian ethnographies 
have explored how MD affects patients’ personhood, both within the rehabilitation 
clinic and in a broader societal context,9 and scholar Masae Kato has investigated the 
impact of culture on MD patients’ attitudes towards personalized medicine, or gene-
based treatments that have promise for treating the dystrophinopathies.10 Like Kato, 
                                                        
7 Vololona Rabeharisoa and Michel Callon, Le Pouvoir des Malades: l’Association Française Contre les 
Myopathies & la Recherche (Paris: Presses de l’Ecole des Mines de Paris, 1999). 
8 Michel Callon and Vololona Rabeharisoa, “The Growing Engagement of Emergent Concerned Groups 
in Political and Economic Life: Lessons from the French Association of Neuromuscular Disease 
Patients,” Science, Technology, & Human Values 33, no. 2 (2008): 230-261, doi: 
10.1080/0308514042000176711; Vololona Rabeharisoa, “From Representation to Mediation: The 
Shaping of Collective Mobilization on Muscular Dystrophy in France,” Social Science & Medicine  62, 
no. 3 (2005): 564-576, doi: 10.1016/j.socscimed.2005.06.036; Vololona Rabeharisoa, “The Struggle 
Against Neuromuscular Diseases in France and the Emergence of the ‘Partnership Model’ of Patient 
Organisation,” Social Science & Medicine 57, no. 11 (2003): 2127-2136, doi:10.1016/S0277-
9536(03)00084-4; Vololona Rabeharisoa and Michel Callon, “Patients and Scientists in French Muscular 
Dystrophy Research,” in States of Knowledge: The Co-Production of Science and Social Order, ed. 
Sheila Jasanoff, 142-160 (New York: Taylor & Francis Group, 2004). 
9 Thomas Abrams, Jenny Setchell, Patricia Thille, Bhavnita Mistry, and Barbara E. Gibson, “Affect, 
Intensity, and Moral Assemblage in Rehabilitation Practice,” BioSocieties 14, no. 1 (2019): 23-45, doi: 
10.1057/s41292-017-0061-4; Barbara E. Gibson, Nancy L. Young, Ross E. G. Upshur, and Patricia 
McKeever, “Men on the Margin: A Bourdieusian Examination of Living into Adulthood with Muscular 
Dystrophy,” Social Science & Medicine 65, no. 3 (2007): 505-517, doi: 
10.1016/j.socscimed.2007.03.043.  
10 Masae Kato, “Genomics and Cure: Understanding Narratives of Patients with Duchenne Muscular 
Dystrophy in Japan,” Anthropology & Medicine 25, no. 1 (2018): 85-101, doi: 
10.1080/13648470.2018.1427695. See also Masae Kato and Margaret Sleeboom-Faulkner, “Cultures of 
Marriage, Reproduction and Genetic Testing in Japan,” BioSocieties 4, no. 2-3 (2009): 115-127, doi: 
10.1017/S174585520999010X; Masae Kato and Margaret Sleeboom-Faulkner, “Motivations for Seeking 






Callon and Rabeharisoa have also examined the “mutual entanglements” of culture and 
patients’ beliefs about disease and treatment, but on Réunion Island instead.11 
While there has been a boom in work by scholars of science, technology, and 
science (STS) on muscular dystrophy since Rabeharisoa and Callon’s first publications 
on the AMF, the current literature is lacking one critical perspective: that of the 
biomedical professionals who are so often presumed to objectively discover new truths 
about MD. Additionally, the vast majority of studies have focused on hyper-specific 
cultural contexts – France, Australia, Japan, and Réunion Island. This emphasis is 
understandable; after all, the last letter of STS stands for “society.” However, there is 
also value in “zooming out” and trying to understand the creation of MD itself in the 
minds of scientists and doctors, as these biomedical professionals are arguably the most 
important people involved in MD knowledge production. How did medical 
professionals think about MD when the dystrophies were first discovered, and how has 
that perspective influenced professional understanding of MD today? In the opposite 
direction, how do present ideas about muscular dystrophy impact how scientists view its 
past? This temporal, rather than spatial, perspective is perhaps the realm of historians 
rather than anthropologists and sociologists. 
Yet the few historical treatments of muscular dystrophy that do exist were 
written by biologists who, naturally, approached the subject with a different framework 
than either a historian or a social scientist would use. The geneticist Alan E. H. Emery 
and his wife, Marcia L. H. Emery, who also has a scientific background, have written 
                                                        
11 Michel Callon and Vololona Rabeharisoa, “Gino’s Lesson on Humanity: Genetics, Mutual 






by far the most extensive work on the discovery of muscular dystrophy. Their book, The 
History of a Genetic Disease: Duchenne Muscular Dystrophy or Meryon’s Disease, is 
the current authoritative source on the history of MD, but the authors themselves admit 
that rather than make any grand analytical claims, their work instead aims primarily to 
recognize the achievements and contributions of the English physician Edward Meryon, 
who was the first to systematically describe (the evidently poorly named) Duchenne 
muscular dystrophy.12 After arguing for the preeminence of Meryon as the father of 
MD, the book reads as a timeline of major scientific findings—which is not unexpected, 
as their target audience is likely biologically minded as well. Finally, the neurologists 
Kenneth L. Tyler, J. M. S. Pearce, and Corrado Angelini have also contributed to the 
literature on the early descriptions of MD, but none of these authors go much beyond 
retracing the path forged by the Emerys.13 Therefore, there remains a significant lacuna 
of scholarship by those in the humanities on how and why biomedical professionals’ 
views of muscular dystrophy have changed so radically since MD was first described; it 
is this gap that this research attempts to fill. 
 Analytical Framework 
The scholarship on muscular dystrophy completed here complements the work 
of other STS scholars who have, in taking an anthropological and/or historical approach 
                                                        
12 Alan E. H. Emery and Marcia L. H. Emery, The History of a Genetic Disease: Duchenne Muscular 
Dystrophy or Meryon’s Disease, 2nd ed. (New York: Oxford University Press, 2011), xv. 
13 Kenneth L. Tyler, “Origins and Early Descriptions of ‘Duchenne Muscular Dystrophy,’” Muscle & 
Nerve 28, no. 4 (2003): 402-422, doi: 10.1002/mus.10435; J. M. S. Pearce, “Early Observations on 
Duchenne-Meryon Muscular Dystrophy,” European Neurology 54, no. 1 (2005): 46-48, doi: 
10.1159/000087386; Corrado Angelini, “Muscular Dystrophy,” in Handbook of Clinical Neurology, ed. 






to studying various other illnesses, stridently argued for the recognition of the biosocial, 
rather than strictly biological, nature of disease.14 The belief in the importance of 
studying the social aspects of disease reflects a larger trend in STS studies. The theory 
of “coproduction,” as pioneered by Sheila Jasanoff and Jenny Reardon, proposes that 
scientific knowledge “is not a transcendent mirror of reality. It both embeds and is 
embedded in social practices, identities, norms, conventions, discourses, instruments 
and institutions – in short, all the building blocks of what we term the social.”15 The 
idea that science is somehow subject to “the social” is foreign to many outside of STS 
studies; the anthropologist Emily Martin has aptly described the natural sciences as 
citadels because they “are heir to processes that have left most of us thinking they are 
set apart from the rest of history and society.”16 But arguing in favor of coproduction is 
not to make the case that society and culture create immutable biological fact. The code 
of DNA is made of four distinct chemical bases; that was true (although unknown) two 
hundred years ago just as it is today and just as it will be two hundred years from now, 
regardless of time or place. Instead, to use a lens of coproduction is simply to suggest 
that there is something valuable in situating scientific discovery and innovation in a 
larger social, cultural, or even political context. 
Instead of speaking in terms of coproduction, the motivation for this 
methodological approach can also be stated more generally by borrowing from the 
                                                        
14 Credit for the notion of biosociality belongs to Paul Rabinow, “Artificiality and Enlightenment: From 
Sociobiology to Biosociality,” in Anthropologies of Modernity: Foucault, Governmentality, and Life 
Politics, ed. by Jonathan Xavier Inda, repr. (New York: Blackwell, 2005; New York: Zone, 1991), 181-
193, doi: 10.1002/9780470775875.ch7. Citations refer to the Blackwell edition. 
15 Sheila Jasanoff, “The Idiom of Co-Production,” in States of Knowledge: The Co-Production of Science 
and Social Order, ed. Sheila Jasanoff (New York: Taylor & Francis Group, 2004), 3. 
16 Emily Martin, “Anthropology and the Cultural Study of Science,” Science, Technology, & Human 





sociologist Nikolas Rose. Drawing from the philosopher Ludwik Fleck’s ideas on styles 
of thought, Rose writes: 
A style of thought is a particular way of thinking, seeing, and practicing. 
It involves formulating statements that are only possible and intelligible 
within that way of thinking… A style of thought is not just about a 
certain form of explanation, about what it is to explain, it is also about 
what there is to explain. That is to say, it shapes and establishes the very 
object of explanation, the set of problems, issues, phenomena that an 
explanation is attempting to account for. The brain, for the contemporary 
sciences of the brain, is not what it was in the 1950s; the cell, in cellular 
biology, is not what it was in the 1960s; ‘the gene’—if it still makes 
sense to call it that—is not what it was before genomes were sequenced, 
and so on. The new style of thought that has taken shape in the life 
sciences has so modified each of its objects that they appear in a new 
way, with new properties, and new relations and distinctions with other 
objects.”17 
Here, Rose is arguing that new styles of thought not only change the discourse around a 
subject but also the meaning of a subject; this is strikingly clear when considering the 
life sciences. Just as the brain and the gene are envisioned completely differently now 
than they were fifty years ago, disease, and, on a smaller scale, muscular dystrophy, are 
different at their core than they were in the pre-genomic age. It is this evolving 
language—what Kaushik Sunder Rajan calls the “shifting grammar of life itself”—and 
its effects that I investigate in this research.18 
                                                        
17 Nikolas Rose, The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First 
Century (Princeton: Princeton University Press, 2009), 29. 
18 Kaushik Sunder Rajan, Biocapital: The Constitution of Postgenomic Life (Durham: Duke University 





Background on Muscular Dystrophy 
Today, biomedical professionals understand the dystrophinopathies as recessive 
diseases caused by mutations in the dystrophin gene, which is located on the X 
chromosome. As a note, scientific convention dictates that genes are italicized while 
proteins are not; therefore, dystrophin refers to the gene, while dystrophin refers to the 
protein. Because the gene associated with DMD and BMD is X-linked and recessive, 
the dystrophinopathies almost exclusively affect boys, as males who inherit a 
dysfunctional copy of dystrophin from their mothers do not have an extra X 
chromosome that can compensate by producing normal dystrophin protein. Normally, 
dystrophin is involved in a large protein complex that physically links structural 
components of a cell, called the cytoskeleton, to a supporting network of proteins and 
sugars outside of the cell, called the extracellular matrix. Because skeletal muscle cells 
are constantly contracting and relaxing, the muscle cell membrane, called the 
sarcolemma, experiences enormous stress. The dystrophin protein acts as a spring, 







Figure 1: Dystrophin Links the Cytoskeleton to the ECM 
A highly simplified diagram of how dystrophin connects a muscle cell’s cytoskeleton to 
the extracellular membrane via a protein complex, thus allowing the cell membrane to 
stretch without tearing.  
In cells that produce zero (i.e. skeletal muscle cells from DMD patients) or only 
minimal (i.e. skeletal muscle cells from BMD patients) functional dystrophin protein, 
the cell membrane is susceptible to wear and tear. If the sarcolemma does not remain 
intact, small molecules that are toxic to the muscles can freely enter the cells, resulting 
in cell death. This cell death triggers constant skeletal muscle regeneration, which in 
turn signals prolonged inflammatory responses and fibrosis, which is the build-up of 
connective tissue in inappropriate places.19  
The continual cycle of cell death and fibrosis therefore explains one of the most 
distinctive clinical features of the dystrophinopathies: although DMD and BMD patients 
                                                        
19 Guiraud et al., “The Pathogenesis and Therapy,” 281. While a number of more recent reviews on the 
pathogenesis of muscular dystrophy exist (this one was published in 2015), Guiraud et al. was written in 
collaboration by the primary investigators of the three labs that were in competition to discover 





have unusually large muscles, especially in the calves, they are extremely weak. In 
DMD patients, this weakness is noticeable in early childhood; by the time DMD 
patients are three to five years old, the muscle damage is irreparable. The muscle 
weakness progresses to the point where afflicted children are completely wheelchair-
dependent by age twelve and die of heart failure at around eighteen years of age. Becker 
patients, on the other hand, experience later-onset skeletal weakness. Depending on 
their levels of dystrophin deficiency, some people with BMD can remain ambulatory 
into adulthood and survive well into middle age.20 
While most treatments for muscular dystrophy merely attempt to manage 
symptoms, more effective therapeutics are soon on the horizon. In 2015, just three 
weeks after being the first to undergo a novel gene therapy treatment, Connor Curran 
was running up the same stairs that he could not walk up before. Five years later, he 
was playing and jumping like any nine-year-old boy. And as of August 2020, three 
“exon-skipping” therapies, designed to allow DMD patients to make truncated, yet still 
functional, dystrophin had been FDA-approved.21 While hopes for a “cure” for 
muscular dystrophy are still distant dreams,22 significant improvements to lifespan and 
overall quality of life are already well within reach. 
                                                        
20 Darras, Urion, and Ghosh, “Dystrophinopathies,” 1-3. 
21 Sujatha Gurunathan, “Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave 
the Way for Personalized Treatments,” MDA, Muscular Dystrophy Association, Nov. 17, 2020, 
https://strongly.mda.org/once-a-wild-idea-successful-first-generation-exon-skipping-therapies-pave-the-
way-for-personalized-treatments. 





Chapter 1: Discovering Muscular Dystrophy 
Gaetano Conte and L. Gioja: Clinical Descriptions 
In 1836, two physicians from Naples, Professor Gaetano Conte and Dr. L. Gioja, 
published a study on two brothers who, from between the ages of 8 and 10, had been 
experiencing progressive enlargement of the muscles, particularly in the calves and 
deltoids, and weakness in the legs. The older brother died with signs of cardiomyopathy 
as a young teenager, while the younger brother, Nicola, who appeared to be less heavily 
afflicted by the disease, had survived to adulthood before he was transferred out of 
Conte and Gioja’s care.23 However, Nicola’s condition had deteriorated so much that as 
of his last appointment with Conte and Gioja, he was unable to voluntarily move any of 
his limbs; the only movements came from severe muscle contractures that radiated 
throughout his body.24 When speculating on the cause of the boys’ illness, Conte and 
Gioja hypothesized that the cold climate and the boys’ physically challenging lifestyles 
“caused spasm of the lymphatic vessels so that their valves closed and they could no 
longer carry away muscle waste. The waste products remained in the muscle, causing 
abnormal growth, and spilt over into the blood. The muscular infiltrations resulted in 
increased intermuscular pressures that caused paresis.”25 Much to the doctors’ dismay, 
no autopsy for the older boy was available, meaning they were unable to examine the 
                                                        
23 John R. Bach, "The Duchenne de Boulogne - Meryon Controversy and Pseudohypertrophic Muscular 
Dystrophy," Journal of the History of Medicine and Allied Sciences 55, no. 2 (2000): 168, 
https://muse.jhu.edu/article/15181 
24 Tyler, “Origins and Early Descriptions,” 403. 
25 Gaetano Conte and L. Gioja, “Scrofola del Sistema Muscolare,” Annali Clinici dell’Ospedale degli 






connective intramuscular tissue, which they believed would allow them to determine if 
their theory of a malfunctioning “nutritional” (metabolic) process was correct.26 Despite 
the lack of histological evidence, the clinical details of the case, from the boys’ growing 
weakness in the limbs to the hypertrophic muscles to the signs of heart failure, suggest 
that the patients suffered from what would eventually be known as muscular dystrophy. 
Yet Conte and Gioja never continued their studies; perhaps they never again came 
across individuals who exhibited similar symptoms. Ultimately, the lack of data (and 
the paper’s improper citation in a book summarizing foreign medical studies) pushed 
their work into obscurity.27 A decade would pass before another presumable case of 
MD was documented. 
Richard Partridge: Macroscopic Histological Analysis 
Richard Partridge was the next to present a case study of what was most likely 
Duchenne muscular dystrophy. In a briefing given to the Pathological Society of 
London in November of 1847, Partridge spoke of a 14-year-old boy who, over the past 
five years, had increasingly experienced general paralysis. Unlike Conte and Gioja, 
however, Partridge had access to autopsy results: 
On the post-mortem examination the spinal canal was found to contain 
about 3ss. of fluid, the cord being healthy… The deltoid and 
sternomastoid muscles had undergone fatty degeneration. The calves 
(which were larger than natural, and had, during the progress of the 
paralysis, become permanently contracted) presented a greater degree of 
fatty degeneration in their muscular structure than the upper extremities, 
the soleus and gastrocnemius being more affected also than the flexor 
                                                        
26 Tyler, “Origins and Early Descriptions,” 403. 





longus pollicus; neither the nerves or [sic] tendons had undergone 
change.28 
Like most DMD patients, the boy that Partridge examined had a normal spinal cord and 
nerves, and he exhibited the characteristic enlarged, weakened calves. However, it is 
also important to note that Partridge’s phrasing indicates that he only observed the 
tissues macroscopically and not microscopically. Thus, while many recognize Partridge 
for providing the first autopsy results of a Duchenne muscular dystrophy patient, the 
lack of microscopic evidence raises a sliver of doubt about the accuracy of a DMD 
diagnosis. 
William J. Little: Microscopic Histological Analysis 
In the same year that Partridge’s briefing on his presumed MD patient was 
published, surgeon William J. Little was also taking note of two brothers who were 
experiencing similar symptoms. In fact, the timing of Little’s initial observations, which 
came two months before Partridge’s, in addition to similarities between the autopsy 
results, has led the Emerys to suggest that the elder of the two brothers was in fact the 
same patient that Partridge described.29 Little’s findings, which were not published until 
1853, detailed the case of two brothers, aged twelve and fourteen. Neither had been 
born paralyzed or with any visible deformities, but over time, their conditions had 
steadily declined. The elder of the brothers had fared the worst, and Little described him 
as having a “peculiar” gate, with calf muscles that looked as if they should have 
belonged to a grown man. By the time Little had the chance to observe them, both 
                                                        
28 Richard Partridge, “Fatty Degeneration of Muscle: Report of Proceedings to the Pathological Society of 
London,” London Medical Gazette (New Series) 5, no. 29 (1847): 944, http://opacplus.bsb-
muenchen.de/title/10431646/ft/bsb11043535?page=968. 





brothers’ conditions had advanced so far that, when pulled up into a standing position, 
they could not stand on their own.30  
While Little’s detailed clinical descriptions mostly reiterated what Conte, Gioja, 
and Partridge had previously described, a single sentence in his report suggests that he 
was the first to request a microscopic analysis of the tissues. Under Little’s direction, a 
Dr. Parker had “kindly submitted these structures to a minuter [sic] examination [and] 
detected ‘granular’ evidences of inflammation in the matter scraped from the arachnoid 
[a membrane surrounding the brain and spinal cord].”31 Despite having new, if 
extremely limited, evidence about the brothers’ affliction, it seems that Little was no 
longer interested in studying the disease himself; after all, the details of the case were 
relegated to a footnote in a book that he published six years later. However, he may 
have used some of his lingering curiosity to direct a colleague’s attention to the boys’ 
“fatty degeneration of muscle”; only five years later, Edward Meryon, a fellow member 
of the Royal Medical and Chirurgical Society, would revisit the family of the brothers 
that Little had studied.  
Edward Meryon: Clinico-Pathological Analysis 
Although others before him had described patients with dystrophinopathies, 
Edward Meryon was the first to conduct both clinical and pathological studies of the 
disease systematically. As the Emerys write, “it was Meryon’s great contribution to 
realize the similarity among the various cases and, most significantly, that they 
                                                        
30 William J. Little, On the Nature and Treatment of the Deformities of the Human Frame: Being a 
Course of Lectures Delivered at the Royal Orthopaedic Hospital in 1843 (London: Longman, Brown, 
Green & Longmans, 1853), 14-16, https://archive.org/details/b21289141/page/n5/mode/2up?q=feed. 





represented a specific and unique disease entity.”32 Besides claiming that muscular 
dystrophy, which he called granular degeneration of the voluntary muscles, was a 
pathology distinct from other muscle-degenerating, paralytic diseases, Meryon also 
recognized that MD is caused by a problem in the muscles themselves (i.e. not in the 
spinal cord) and that it frequently appears in families, almost always in males. Given 
these many early contributions, Meryon is often considered to have produced the first 
“complete” clinico-pathological description of MD.33  
Considering Meryon’s eminence in the medical field, both in his own time and 
today, surprisingly little is known about his early life. There are ample records, 
however, from his time in medical school. Meryon was evidently an outstanding 
student, receiving a gold medal and first certificate in anatomy, a certificate of honor in 
physiology, and a certificate of honor in practical anatomy.34 Notably, the classes in 
which Meryon received awards covered both “changes produced in the structure of the 
muscular system from disease” and “spasmodic and paralytic affections.”35 His 
excellence in these subjects, along with his membership in various well-respected 
professional organizations, including the Royal Medical and Chirurgical Society (to 
which both Partridge and Little belonged), would serve him well as he began to grow 
interested in muscle diseases. 
On December 9th, 1851, Meryon presented a paper titled “On Granular and Fatty 
Degeneration of the Voluntary Muscles.” Meryon believed that the work he was about 
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to present was “of more than ordinary interest,” as he had found individuals from three 
different families who seemed to share the same unfamiliar disease.36 He had 
discovered family “P” in 1848 when he was asked to consult on the case of a boy who, 
despite having progressed normally until late childhood, had begun to lose the ability to 
walk. When Meryon examined the child, simply known as the “Hon. Geo. P.,” he found 
that “the power of the muscles of the upper extremities was diminishing also, 
notwithstanding that the muscular mass of the body and limbs did not appear to have 
diminished, but, on the contrary, he had grown well and had gained in flesh.”37 Just two 
years after this initial assessment, Geo. P. died, unable to walk or even stand. Meryon 
was immediately informed upon his patient’s death and was able to conduct an autopsy 
just twenty-two hours later.38 The macroscopic examination of the spinal cord and 
muscle tissue revealed the results expected of Duchenne MD patients: the spinal cord 
and membranes appeared to be perfectly healthy, while the voluntary muscles were 
atrophied and clearly diseased. However, microscopic analysis revealed that “the striped 
elementary primitive fibres were found to be completely destroyed, the sarcous element 
being diffused, and in many places converted into oil globules and granular matter, 
whilst the sarcolemma or tunic of the elementary fibre was broken down and 
destroyed.39 To illustrate these findings, Meryon included hand-drawn images of what 
he saw under the microscope (Figure 2). 
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Figure 2: “Degeneration of the Voluntary Muscles” 
Meryon’s original captions for these illustrations are as follows: A. “Diseased Muscles, 
the transverse striae appearing faintly in places. Drawn from the preparation.” B. 
“Diseased Muscle from the upper extremities, the transverse striae beginning to 
disappear and granular taking their place.” C. “Diseased Muscle from the lower 
extremities, the transverse striae having disappeared.” D. “Diseased Muscle from the 
lower extremities, showing little more than granular matter.”40 
Meryon’s work was ground-breaking not only because he was the first to study 
the affected tissues at a microscopic level, but also because he had uncovered a string of 
other patients who suffered from the same symptoms. His interviews with Geo. P.’s 
parents revealed that they had three younger sons who had all started to show the same 
                                                        





signs of weakness in the extremities, while their six daughters remained unaffected.41 
Additionally, two other families also reported having two sons each with similar 
conditions; the oldest boy from family “H” was in fact the same patient that Partridge 
and Little had previously observed.42 These results led Meryon to conclude that this 
degeneration of the voluntary muscles ran in families and exclusively affected males; 
that is, the disease was heritable. 
Duchenne de Boulogne: The “Discoverer” of DMD 
Considering all of Meryon’s contributions to understanding the 
dystrophinopathies, including being the first to recognize DMD as a distinct, previously 
undescribed disease, it is curious that it is not his name associated with this form of 
muscular dystrophy. Instead, the eponymous honor belongs to Guillaume-Benjamin 
Amand Duchenne, better known as Duchenne de Boulogne. By his own admission, 
Duchenne did not come across his first patient with DMD until 1858; he then published 
his findings in 1861.43 Notably, this was a decade after Meryon and two decades after 
Conte and Gioja had documented their discoveries of muscular dystrophy. Furthermore, 
his work only began to extend beyond the clinic ten years after he consulted with his 
first DMD patient when he observed autopsy reports. Even then, the autopsy reports 
were not for patients of his own; they were from two separate publications, one in 1863 
and the other in 1866, on two German boys who had died from the same symptoms that 
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Duchenne had observed.44 In response to criticism over his lack of anatomical evidence, 
Duchenne finally observed muscle tissue from a DMD patient for himself in 1865 using 
a device of his own invention: the “histological harpoon,” as it was known in England, 
which was the first instrument designed to collect muscle tissue samples from live 
patients.45 While the development of a muscle biopsy tool was significant, in many 
ways Duchenne’s work did little more than retrace what Conte, Gioja, Partridge, Little, 
and Meryon had cumulatively described years before him.  
Although he was not nearly the first person to describe DMD, Duchenne 
seemingly had no qualms about claiming the title of “discoverer” for himself, even 
though he explicitly stated his familiarity with Meryon’s work.46 While some, like the 
Emerys, have given Duchenne the benefit of the doubt,47 it is clear that he purposely 
tried to undermine Meryon’s findings. In three separate publications, Duchenne wrote 
that Meryon had in fact observed atrophie musculaire graisseuse progressive, a term 
Duchenne used to describe various neuromuscular diseases like poliomyelitis and spinal 
muscular atrophy, rather than the disease that would eventually be classified as DMD.48 
Neurologist John R. Bach in particular has stridently criticized Duchenne, scathingly 
remarking that “The fact that subsequent historians and neurologists credited him with 
priority is not due to Duchenne de Boulogne’s achievement in science, but rather his 
skill in deliberately obscuring the contributions of others and claiming, falsely, the glory 
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for himself.”49 As Bach summarizes, Duchenne repeatedly disparaged the work of other 
early neurologists who were studying muscular and neuromuscular diseases, alluded to 
unpublished and apparently nonexistent memoires in which he described DMD cases 
predating Meryon’s discoveries, claimed to have cured at least one DMD patient, and 
discredited Meryon by arguing that Meryon had mistakenly diagnosed his patients.50 In 
sum, the evidence indicates that Duchenne consciously obfuscated the true origins of 
the discovery of the dystrophinopathies. 
Forgetting Meryon: 19th Century Attitudes Surrounding Microscopy 
Considering Duchenne’s actions, an obvious question arises: how and why was 
Duchenne so successful in claiming the discovery of DMD for himself? Situating 
Meryon and Duchenne in the social and technological contexts of their time may 
provide an answer. Today, the microscope is arguably one of the most popular tools 
associated with scientists; STS scholar Ann La Berge states that it may have been the 
primary symbol of biomedicine for a century before the rise of genetic technologies in 
the 1960s.51 Yet this was not always the case. Following the deaths of the classical 
microscopists at the end of the 18th and beginning of the 19th centuries, microscopy 
experienced a dramatic decline. The microscope became associated with “popular” 
science and was “primarily an instrument of amateurs to be used either for display or 
entertainment. In a word, it was a toy.”52 Across continental Europe, scientists 
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continued to view microscopy as a recreational, social activity well into the early 1800s. 
Men would meet at each other’s homes and spend their evenings fiddling with 
microscopes and other hobby instruments.53 Although there is significant debate over 
what caused this century-long break from using microscopes for “serious” science,54 
one factor was that it was difficult to see clear images through them. Through the 18th 
and early 19th centuries, there were no significant improvements to the microscope. 
Thus, people were stuck with the same glass quality and lens size of the same simple 
microscopes that made men like Anton van Leeuwenhoek famous more than a hundred 
years before.55  
The issue of microscope quality was solved in 1826, when British physician 
Joseph Jackson Lister (not to be confused with his son, Joseph Lister, who would 
become famous for pioneering antiseptic surgical techniques) designed an achromatic 
compound microscope that eliminated the spherical aberrations that had previously 
limited the instrument’s practical value.56 However, the invention of this new 
microscope was not associated with an immediate recognition that it could be used to 
study disease, or even that it could be used to study tissue. First, the cost of the 
achromatic microscope was prohibitive, so it did not become widely available until the 
                                                        
53 Jutta Schickore, The Microscope and the Eye: A History of Reflections, 1740-1870 (Chicago: 
University of Chicago Press, 2007), 105. 
54 C.f. Catherine Wilson, The Invisible World: Early Modern Philosophy and the Invention of the 
Microscope (Princeton: Princeton University Press, 1995); Marian Fournier, The Fabric of Life: 
Microscopy in the Seventeenth Century (Baltimore: Johns Hopkins University Press, 1996); Edward G. 
Ruestow, The Microscope in the Dutch Republic: The Shaping of Discovery (New York: Cambridge 
University Press, 1996). 
55 Gerard, L’E Turner, “Eighteenth-Century Scientific Instruments and Their Makers,” in The Cambridge 
History of Science, ed. by Roy Porter, 4:509–35, (Cambridge: Cambridge University Press, 2003), 
doi:10.1017/CHOL9780521572439.023. 
56 Patricia Helen Bracegirdle, “The Establishment of Histology in the Curriculum of the London Medical 






1850s.57 Secondly, there was little interest in histology at the time anyway. Although a 
theoretical framework of tissue classification, pioneered by the French anatomist Marie 
François Xavier Bichat, had been broadly accepted in British medical schools by the 
1820s, the first English-language series to provide a description of the microscopic 
anatomy of the tissues was not completed until 1844.58 Furthermore, differential 
staining, which improves tissue visibility under a microscope, was not developed until 
1852.59 Finally, histology was not incorporated into lessons on general anatomy across 
all British medical schools until 1854, and it took another twenty years before schools 
were required to teach the study of tissue as its own, separate course.60 The slow 
progress between the founding of histology and its mandatory teaching in medical 
institutions suggests that for much of the 19th century, few recognized the importance of 
studying tissue for understanding pathology. Suspicions about the utility of histology, 
and the microscope in general, lingered well into the 1850s in London.61 
Since Meryon’s first observations on muscular dystrophy occurred between 
1848 and 1851, he was working at a pivotal time in the history of modern microscopy 
and histology; while some in London were beginning to see the microscope’s potential 
for providing insight into disease pathogenesis, many others still viewed microscopy as 
merely a gentleman’s hobby. Meryon, as one of the founders of the Microscopical 
Society of London, was firmly in the first camp.62 When he presented his case studies to 
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the Royal Medical Society, however, his histological findings, while intriguing, were 
probably not the most interesting aspect of his talk for many of the members present. 
And when his findings made their way to France, his comments on the muscle tissue 
anatomy of his patients would have met an audience even more indifferent, if not 
hostile, to the microscope.  
The microscopic revival of the 19th century was even slower to reach France 
than England. Like in England, microscopes, especially the new achromatic ones, were 
expensive. However, resistance to microscopy, and therefore anatomical pathology, was 
also driven by the still-prevailing theories of humoral pathogenesis (which could not be 
studied via microscope) and “radical empiricism,” which prioritized the pure senses, 
unobstructed (or unaided) by any tools.63 If microscopy was beginning to gain more 
widespread acceptance in London from the mid- to late 1850s, tensions between the 
upstart microscopists and the established, anti-microscopy clinicians were coming to a 
head in Paris. From 1854 to 1855, the Academy of Medicine held thirteen debate 
sessions dedicated to discussing the utility of microscopy; the older, anti-microscope 
faction won.64 However, tides changed in the 1860s as France began to feel pressure 
from Germany, whose own surgical techniques, anatomical and physiological research, 
and overall medical training had rapidly surpassed those of France. National feelings of 
inferiority and “French degeneracy” sparked competition and paved the way for the 
acceptance of new technologies and medical instruments, including the microscope. 
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Thus, it was only until the mid-1860s that French physicians, about a decade after 
British doctors, grew to see microscopic histological analysis as an essential part of the 
biomedical research process.65 
France’s history with microscopy explains in part why Duchenne was able to 
brush Meryon’s work aside. The first time Duchenne publicly disagreed with Meryon’s 
diagnoses was in 1855, the last year of the Academy of Medicine’s debates on 
microscopy.66 Duchenne was not one of these early adopters of the microscope, as part 
of his criticism included Meryon’s heavy focus on anatomical pathology rather than 
clinical symptoms.67 There would have been few established French physicians that 
would have disagreed with him. Yet soon after, Duchenne himself came under fire from 
colleagues abroad for his lack of pathological evidence in his various publications on 
potential new muscular and neuromuscular diseases. This may have been what led him 
to provide some, if very little, histological evidence in his 1861 edition of a book on 
“new” degenerative diseases.68 However, it was not until 1872 that he fully addressed 
this criticism: “I have been much blamed abroad for having, in the different 
pathological investigations which I have published neglected and despised pathological 
anatomy, that branch of science inseparable from all good clinical work. I recognised 
the reproach, and wished to expose myself to it no longer.”69 While it is difficult to 
determine if Duchenne truly had a change of heart concerning microscopy or if he was 
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simply responding to his London associates’ pressure, by 1872, the resurgence of 
microscopy was well under way in France. Unsurprisingly, Duchenne’s histological 
analyses of DMD patients yielded the same results that Meryon had described much 
earlier before: an increase in fibroid and connective tissue, fat vesicles in the sheaths of 
the sarcolemma, and disruptions in the transverse striations of the muscle fibers.70 Yet 
Duchenne had already succeeded in sweeping Meryon under the rug, his microscopic 
descriptions discredited and forgotten. Notes from George Poore, who in 1883 compiled 
and translated into English selections from many of Duchenne’s publications, 
demonstrate the irony of the situation: 
Duchenne seems to have been blamed because he devoted his attention 
more to bed-side observation than to microscopical anatomy. The fact 
was that he had no special talent for the pursuit of morbid histology, and 
although latterly he devoted some attention to the subject, and was one 
of the first who attempted to fix microscopic results by the aid of 
photography, he did not succeed in adding to our pathological 
knowledge, and one cannot but feel that anything which took a man of 
his habit of mind away from the bed-side, where he was unequalled, did 
not, to say the least, help the advance of medical science. A wise division 
of labour has been, and will be, a powerful cause of the advance of 
knowledge, and a great clinical observer should rather be encouraged 
than otherwise to leave the delicate work of histology to those whose 
natural talents lead them to devote their best energies to the pursuit of 
it.71 
Poore gently reproaches Duchenne’s lack of histological evidence, balancing his 
critique by emphasizing Duchenne’s unparalleled clinical skills. It should be up to more 
a skilled microscopist, he writes, to study the diseased tissue. These detailed 
descriptions of DMD histology, though, had already been completed by a “skilled 
microscopist” – Edward Meryon. Yet later in the text, he explicitly states that Meryon’s 
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“case of muscular degeneration in the Medico-Chirurgical Transactions for 1854 and 
1866 refers in reality… to pseudo-hypertrophic paralysis,” a disease that was already 
well-documented.72 By the early 1880s, Meryon’s observations had been forgotten; 
from then on out, Duchenne’s name would be associated with this form of muscular 
dystrophy. 
What Does it Mean to “Discover” a Disease? 
Largely thanks to the Emerys, the current works on the history of muscular 
dystrophy are nearly unanimous in their belief that Duchenne should not be credited as 
the first to discover MD. However, none of the literature has attempted to explain how 
“Duchenne” became the eponym. By placing Meryon’s and Duchenne’s in a broader 
social context, it becomes clear that the microscope, in conjunction with the newly 
emerging field of histology, is responsible for the name of the disease. However, it is 
also worth considering why these same scholars are so quick to name Meryon as the 
“true” discoverer of the disease; he certainly was not the first to provide a detailed 
clinical description. Neither the Emerys, Tyler, Pearce, Accardo, nor any other scientist 
who has written about the discovery of muscular dystrophy, to my knowledge, 
explicitly addresses this concern. The circular answer seems to be that Meryon should 
be credited simply because Duchenne should not be. Yet once again, understanding the 
connections between microscopy and muscular dystrophy reveals why scientists have 
argued for Meryon’s primacy.  
                                                        





When the Emerys published the first edition of their book on DMD (or, as they 
would call it, Meryon’s disease), doctors were still using tissue analysis as the final step 
in diagnosing muscular dystrophy.73 The resurgence of microscopy that had begun in 
the 1800s continued for another century as microscopy continued to gain respect and 
became an important tool for diagnosing the dystrophinopathies. Thus, it appears that 
20th century conceptions about DMD pathology were reflected onto the past, 
influencing who biomedical professions labeled the “discoverer” of MD. As a result, 
scientists do not credit Partridge as the father of muscular dystrophy because he only 
examined tissue samples from an MD patient macroscopically. Similarly, Little’s 
discovery is dismissed (even though some scholars have suggested that Little’s clinical 
descriptions of the progression of DMD were even more detailed than Meryon’s)74 
because he only used the microscope in a limited manner and did not present his 
histological observations as essential to his conclusions about the disease. Conte and 
Gioja do not figure into the conversation of discovery at all, as they solely focused on 
clinical descriptions since they did not have the opportunity to observe the diseased 
tissues.  
The work of the famed neurophysiologist Charles Bell provides further support 
for the argument that current medical understandings influence the conception of 
disease discovery. Bell almost certainly described a single case of Becker muscular 
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dystrophy, which is the milder of the two dystrophinopathies, in 1830, six years before 
Conte and Gioja’s description of a Duchenne muscular dystrophy patient and more than 
a century before BMD was recognized as distinct from DMD.75 In his book, The 
Nervous System of the Human Body, Bell describes… 
… a young gentleman about eighteen. All the muscles of the lower 
extremities, the hips, and the abdomen, are debilitated and wasted… The 
upper part of the body, the shoulders, and arms, are strong… There is a 
slight curvature or projection of the lumbar part of his spine. He is weak, 
and subject to palpitations on going up stairs; his tongue is coated… The 
paralytic debility of the muscles came on gradually: he was first sensible 
of it at a public school, about eight years ago. It began with a weakness 
in the thighs, which disabled him from rising; and it is now curious to 
observe how he will twist and jerk his body to throw himself upright 
from his seat.76 (clxiii).  
Bell’s observations, combined with the boy’s extended lifespan and later onset, align 
perfectly with clinical descriptions of BMD today; he even describes the odd technique 
the teenager used to maneuver himself from a chair into a standing position, part of 
classical physical tests for muscular dystrophy. Yet as with the doctors before Meryon, 
namely Conte and Gioja, Partridge, and Little, who described DMD, experts have been 
reluctant to give Bell credit for his discovery. But why? As the Emerys write at the end 
of their discussion about Bell, despite the fact they obviously believe Bell did indeed 
observe a BMD patient, “Without muscle pathology, however, the diagnosis of 
muscular dystrophy cannot be certain.”77 From Duchenne until the late 20th and early 
21st centuries, the authority of the microscope has clearly influenced the way scientists 
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discuss the history of MD. In short, the technology that is perceived to most accurately 
describe the disease determines who is credited with its discovery. This theme of the 
importance of technology in shaping conceptions of disease holds true not only when 
discussing the discovery of MD, but also when considering how ideas about diagnosis 





Chapter 2: Methods of Diagnosis 
Diagnosing the Dystrophinopathies: From Microscopy to DNA Sequencing 
When Meryon sketched what he saw under his microscope after observing the 
muscle tissue of his first DMD patient, little did he know that he was foreshadowing the 
future of Duchenne and Becker muscular dystrophy diagnosis for the next one hundred 
and fifty years. Until the end of the 20th century, the primary way to confirm that an 
individual had either DMD or BMD was by conducting a muscle biopsy;78 a trained 
pathologist could easily observe the differences between normal and healthy skeletal 





                                                        







Figure 3: Skeletal Muscle Histology: DMD vs Normal Biopsy Samples 
The DMD tissue on the top, clearly distinguishable from the healthy skeletal tissue on 
the bottom, shows fat (white) and muscle degeneration (pink) around the myocytes 
(red).79 
Yet the resurgence of the microscope had other long-lasting effects on MD diagnosis. 
The development of histology precipitated a dramatic change in how physicians 
examined their patients, as studying tissue samples was an entirely new way for doctors 
to collect clinical data. As a result of this shift from focusing solely on the outward 
expression of disease, “the boundaries between ‘laboratory’ and ‘clinical’ practices 
became increasingly fuzzy, and changes in patients’ tissues and vital fluid became part 
of the ‘pathological signs’ of a disease.”80 Thus, while muscle biopsy remained the 
definitive method to diagnose a patient with DMD or BMD, scientists also began 
                                                        
79 Dongsheng Duan et al., “Duchenne Muscular Dystrophy,” Nature Reviews Disease Primers 7, no. 13 
(2021): 3, doi: 10.1038/s41572-021-00248-3. 
80 Ilana Löwy, “Labelled Bodies, Classification of Diseases and the Medical Way of Knowing,” History 





pursuing other laboratory-based assays for identifying patients with muscular 
dystrophy. 
By the late 1940s, scientists began to consider the idea that there might be a way 
to diagnose MD by analyzing patients’ blood. French scientists Jean-Claude Dreyfus 
and Georges Schapira started by studying the enzymes involved in muscle glycolysis, 
which is the process by which muscle cells turn sugar into energy.81 Although they 
found that serum levels of various enzymes were elevated in muscular dystrophy 
patients, the most sensitive serum enzyme test was not created until 1958. A group of 
Japanese biochemists led by Setsuro Ebashi found that out of nineteen patients with 
progressive muscular dystrophy (a term which includes DMD and BMD), 
approximately 70% showed significantly increased levels of creatine phosphokinase 
activity.82 Creatine phosphokinase, often abbreviated as either CK or CPK, is primarily 
present in muscle tissue and helps muscles contract. When there is muscle damage, 
however, CK leaks into the bloodstream and therefore leads to elevated serum levels.83 
After Ebashi et al.’s initial discovery, more and more sensitive assays for detecting 
elevated CK levels were devised, significantly improving the reliability of CK tests. In 
fact, Victor Dubowitz, famous for his work in pediatric muscle diseases, was so 
confident in the diagnostic abilities of CK testing that in 1976, he concluded that 
“Duchenne muscular dystrophy can be diagnosed with confidence before it is clinically 
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apparent, and excluded with certainty where it may have seemed clinically obvious.”84 
This is a critical point; for the first time, scientists had created a test that they believed 
could not only diagnose patients with DMD, but could also predict which patients 
would eventually show the symptoms of the disease.  
While biochemists were studying enzyme levels of muscular dystrophy patients, 
other scientists were interested in the genetic component of MD; these researchers were 
some of the first molecular biologists. Although Meryon recognized that MD often ran 
in families and almost exclusively occurred in males, the language of genetics did not 
yet exist. By the late 1950s, however, the X-linked mode of inheritance of muscular 
dystrophy had been well established, and interest in the potential genetic underpinnings 
of the disease skyrocketed.85 A few decades later, the development of new genetic 
technologies and the work of countless scientists culminated in 1986 and 1987, when 
Louis Kunkel and associates identified the location, or locus, of the “DMD gene,” the 
gene itself, and the gene’s protein product, which they decided to name “dystrophin.” 
Furthermore, they discovered that BMD was associated with mutations in the 
dystrophin gene as well.86  
It is difficult to overstate the astounding nature of Kunkel’s lab’s findings. For 
the few other diseases that had been genetically mapped at this time, scientists had 
already known with relative certainty the identity of the mutated protein product 
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associated with the disease phenotype. The search for the DMD locus, on the other 
hand, was a blind hunt; all that was known was that the gene of interest was located on 
the X chromosome. As such, muscular dystrophy was the first disorder for which 
scientists located and identified the defective gene without having any prior knowledge 
about what kind of protein it might encode;87 on the flip side, it was also the first time 
that a disease-related protein had been identified from analysis of its gene.88 Kunkel’s 
unprecedented success demonstrated the potential of genetics, scientists believed, to 
provide more “accurate” insight into the pathological source of any disease with a 
genetic component. This logic thus inspired arguably the most ambitious undertaking in 
the history of science: the Human Genome Project (HGP). The effort to identify each 
individual component of humanity’s DNA would change the process of diagnosing MD 
once again. 
Although some genetic tests for diagnosing muscular dystrophy existed before 
the completion of the HGP, these assays identified DMD in only about two-thirds of 
boys who exhibited clear clinical symptoms of the disease.89 The successful completion 
of the HGP, however, led the National Human Genome Research Institute (NHGRI) to 
invest 70 million dollars in DNA sequencing technologies with the hope of making 
them cheaper, faster, and more widely available.90 The rapid development of high-
throughput sequencing was a step towards realizing a new diagnostic test that scientists 
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hoped would capture all cases of both Duchenne and Becker muscular dystrophies: 
individual DNA sequencing. To understand the process of diagnosis following the 
HGP, I spoke with Dr. Kunkel himself. In a conversation over Zoom, he explained that 
today, MD sequencing is typically done via targeted exome sequencing, that is, 
sequencing of the parts of the gene that code for the dystrophin protein, because it is so 
cost-effective. For around $400, he estimated, a patient can receive a read-out of each 
dystrophin-encoding unit of their DNA.91 
It is perhaps worth summarizing, then, the process of MD diagnosis in the 
present day. In an effort funded by the U.S. Centers for Disease Control and Prevention 
(CDC), 84 clinicians collaborated in 2009 to provide recommendations for healthcare 
providers on how to diagnose MD. The authors write that physicians should “suspect” a 
diagnosis of DMD if, first, they observe a child with abnormal muscle function, or 
second, if they happen to notice an abnormally high CK level when testing “for 
unrelated indications.” The next and final step to confirm a diagnosis of DMD (or 
BMD) is to conduct some kind of genetic test, the type depending on local availability 
and/or reliability. If multiple molecular test options are available, however, dystrophin 
gene sequencing, the authors suggest, will provide the most accurate result.92 
Diagnosing Disease, or Creating Diseases from Diagnoses? 
On the surface, it seems that the advent of new diagnostic technologies would 
make it easier for clinicians to know whether a patient has or does not have one of the 
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dystrophinopathies. But the evolving process of diagnosing muscular dystrophy instead 
reveals underlying epistemological concerns about legitimate ways of knowing, which 
in turn shapes what qualifies as legitimate knowledge. For example, although clinical 
symptoms and elevated CK levels may indicate that a patient has a muscular dystrophy, 
these tests by themselves no longer constitute legitimate ways of knowing if a patient 
has MD. My conversation with Dr. Kunkel further highlighted these points. When 
asked about how muscular dystrophy was diagnosed at the beginning of his career, he 
said:  
So we didn’t know much at the time. Muscle biopsy was how it was 
diagnosed. Carrier females were detected by elevated CK levels, but it 
was very imprecise. And so many women didn’t know they were carriers 
and frequently would have a child with Duchenne [muscular dystrophy] 
before they actually even knew that they were a carrier… You can’t just 
use CK levels anymore, it’s all molecularly done.93 
Kunkel primarily mentioned CK levels in the context of screening for mothers carrying 
a dystrophin mutation that could be passed on to her children, only mentioning CK 
analysis for direct diagnostic purposes at the end of his response, rejecting it as 
something “you just can’t” do anymore. This is a far cry from Dubowitz’s bold 
statement that DMD could be “diagnosed with confidence before it is clinically 
apparent” using a CK assay alone. After the genomic revolution of the late 20th and 
early 21st centuries, CK serum analysis was not sufficient on its own to identify cases of 
MD. 
In general, the history of MD diagnosis follows a larger “ways of knowing” 
trend in biomedicine – the trend of methodological reductionism. As philosopher of 
                                                        





science Michael Ruse writes, “Inspired by the history of science since the Renaissance, 
the methodological reductionist argues that the triumphs of science come through the 
revealing and understanding of ever-smaller entities of nature.”94 In other words, 
scientists have come to believe that there is some higher, “more truthful” truth that can 
be elucidated by thinking on a smaller and smaller scale or by continually subdividing a 
whole into parts. The procedure for diagnosing MD perfectly encapsulates this theory. 
Over time, acceptable ways of confirming diagnosis shifted from a macroscopic scale 
(clinical symptoms) to a microscopic scale (histology) to an enzymatic scale (CK 
levels) to, finally, a molecular scale. And while it is tempting to view this sequence of 
events as a naturally progressing process from less to more accurate, it is more precise 
to see this “narrowing of the evidentiary terrain” as a new way of considering the 
boundaries of the dystrophinopathies as diseases.95  
Indeed, these diagnostic changes have defined what muscular dystrophy is. At 
first, this style of thinking seems counterintuitive; it seems like biomedical professionals 
would have to define a disease first in order to diagnose their patients. But the history of 
muscular dystrophy demonstrates that the process can work in the reverse; diagnosis 
constructs the limits of a disease. When Conte, Gioja, Partridge, and Little came across 
instances of muscular dystrophy, their patients’ outward signs of illness led them to 
conclude that they had observed a disease of weakened muscle. When histological 
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analysis emerged as the next authoritative mode to diagnose individuals, the definitions 
of DMD and BMD were slightly narrowed into “granular and fatty degeneration of the 
voluntary muscles.” In the 20th century, after scientists like Dreyfus, Schapira, and 
Ebashi discovered that DMD and BMD patients had different serum enzyme levels than 
those unaffected by dystrophinopathies, MD became a disease at the biochemical level, 
an enzymatic defect.96 And today, almost every clinician would say that muscular 
dystrophy is a result of a gene mutation. Every paper, book, and essay on muscular 
dystrophy published after the identification of dystrophin cited thus far has described 
MD as either a genetic disease or disorder, and when I asked Dr. Kunkel what he felt 
was the most accurate way to describe the pathological source of DMD, he looked 
obviously perplexed. “It’s genetic.” He replied without hesitation. “It’s a gene mutation 
that causes the absence of dystrophin.”97   
Yet by coming up with new ways to diagnose MD, scientists were 
simultaneously generating new ways to conceptualize MD. The anthropologists 
Margaret Lock and Vinh-Kim Nguyen have more thoroughly described how diseases 
are “made real” by diagnostic procedures: 
Before objects and events can be made phenomenologically real, their 
very existence has to be recognized by a process of naming, ordering, 
and classification. Such recognition, including the diagnosis and 
management of episodes of illness, is the product of culture and does not 
emerge spontaneously from nature. In other words, what will count as 
disease and illness comes about as the result of particular practices 
embedded in specific historical, political, social, and technical 
relationships.98 
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In other words, shifting cultural contexts ascribe legitimacy to certain methods of 
knowledge production (i.e. methods of diagnosis), which in turn influences the 
knowledge produced (i.e. the definition of MD). That this phenomenon has shaped 
understandings of muscular dystrophy becomes clear when returning to the advent of 
the CK serum test. As Dubowitz stated, the CK serum assay not only allowed doctors to 
diagnose cases of muscular dystrophy before the onset of symptoms, but it also allowed 
them to exclude cases that would have otherwise been categorized as DMD based on 
clinical symptoms and histology alone.99 Therefore, Duchenne MD was subdivided into 
even more categories of muscular dystrophy. 
Dr. Kunkel’s thoughts on diagnosis provide additional evidence for this theory 
of disease-creation. When elaborating on how the diagnostic process has changed since 
he first began studying muscular dystrophy, he said: 
Now they do targeted sequencing. Genome sequencing has become, I 
mean, exome sequencing has become so economically feasible. It's like 
400 bucks and you get the whole gene, you get the whole gamut. So if 
you have a child who's a boy who presents with symptoms of muscular 
dystrophy, 90% of the time they will be Duchenne and a dystrophin 
mutation. About 5 to 10% of the time, they will be an autosomal 
recessive form of muscular dystrophy. There are now almost 20 known 
autosomal, recessive dystrophies that look almost identical to Duchenne, 
and they were all picked up. A lot of them are proteins that work with 
dystrophin in the muscle cell membrane. 
It was only after the advent of sequencing technologies that scientists identified these 
other autosomal (i.e. not on the sex chromosomes) recessive muscular dystrophies; had 
acceptable methods for diagnosis not changed following the genomic revolution, they 
would have still been classified as Duchenne. This is particularly interesting because 
                                                        
 





although histology has taken a back seat to molecular techniques, it is still an acceptable 
way to diagnose MD. In their recommendations to physicians, Bushby et al. concede 
that when molecular testing is not readily available, a muscle biopsy can be performed 
(although they do argue that it is “mandatory” to conduct genetic tests on the tissue 
sample to confirm an MD diagnosis). However, if a doctor orders a genetic test, but the 
results do not reveal a known, MD-associated mutation, a muscle biopsy is sufficient to 
diagnose the disease.100 This continued, if begrudging, acceptance of tissue analysis 
even in light of new molecular diagnostic assays is probably a safeguard for the 
instances when a patient symptomatically and histologically presents with muscular 
dystrophy but does not have a known mutation associated with the disease. When this 
conflict between two sanctioned ways of knowing occurs, however, scientists fall back 
on genetics and classify their findings as a novel disease. A case may present exactly 
like DMD at the clinical, microscopic, and enzymatic levels, but the authority of 
molecular technologies means that it is ultimately not classified as the Duchenne type of 
MD. Such a distinction would not have been possible before the naissance of high-
throughput sequencing technologies or the identification of the dystrophin gene. 
Individualized sequencing, then, not only paved the way for another method of 
diagnosis, but further specified the pathological nature of Duchenne (and other forms 
of) muscular dystrophy.  
Ultimately, the history of MD diagnosis demonstrates that at some level, disease 
classification is arbitrary; these categories of diseases are certainly not “natural” or 
“inevitable.” Instead, the current classifications of MD exist because muscular 
                                                        





dystrophy is one of Hans-Jörg Rheinberger’s “epistemic things,” which are “material 
entities or processes – physical structures, chemical reactions, biological functions – 
that constitute the objects of inquiry. As epistemic objects, they present themselves in a 
characteristic, irreducible vagueness. This vagueness is inevitable because, 
paradoxically, epistemic things embody what one does not yet know.”101 On the one 
hand, muscular dystrophy is the “target” of inquiry, yet it is simultaneously defined in 
relationship to the scientists’ concerns. 102 As such, how biomedical professionals define 
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After describing his histological findings, Meryon prefaced his hypotheses about 
the pathological origin of this unfamiliar disease with the following comment: “In 
considering the complex phenomena of disease in the human body, the great difficulty 
is manifestly that of singling out one only of the antecedents which concur to produce a 
given effect, and to point to that as the physical cause.”103 Biomedical researchers are 
still bedeviled by the same challenge nearly two centuries later. Yet while scientists 
continue their search for increasingly more “accurate” biological truths, it is worthwhile 
to pause and consider why said “truths” exist, or why they are constructed in certain 
ways. Again, this is not to make any anti-science claims. This mode of analysis does not 
argue, for example, that scientists are incorrect in saying that the dystrophinopathies are 
linked to, or even caused by, mutations in the dystrophin gene. Rather, considering how 
and why certain “truths” are crystallized is simply a way of recognizing that cultural 
processes have profoundly shaped how scientists understand nature. As Lock and 
Nguyen summarize, “The approach to human disease that characterizes biomedicine 
was neither an inevitable development nor the result of an orderly uncovering of the 
‘true’ causes of illness. Biomedicine is the product of particular historical 
circumstances.”104 This, ultimately, is the notion of “biosociality.” 
What, then, can be said about the biosocial nature of muscular dystrophy? An 
incredible amount – far more than has been covered in this thesis. However, it is clear 
that underlying the entire history of MD research is a narrative around emerging 
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technologies. The development of microscopy, CK serum assays, and genetic tests, each 
of which emerged from their own sociopolitical contexts that are worth exploring with 
an STS lens, not only created and reflected changing attitudes about how to know, but 
also about what there is to know. These technologies quite literally changed what 
muscular dystrophy is at a fundamental level, as “muscular dystrophy” exists as a 
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